Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer

NCT00916123 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Docetaxel
DRUG: Prednisone
DRUG: 177Lu-J591
DRUG: 177Lu-J591
DRUG: 177Lu-J591
DRUG: 177Lu-J591
DRUG: 177Lu-J591

Sponsor

Weill Medical College of Cornell University